Okay, let's tackle this question. The user wants an explanation for a multiple-choice question about which erythromycin preparation is most likely to cause hepatitis with cholestatic jaundice. The correct answer is missing, so I need to figure out which option is correct first.

First, I remember that erythromycin has different formulations. The estolate form is a common one. I think there was a recall or a known adverse effect with that. Cholestatic jaundice is related to liver issues, specifically involving bile flow.

So, the core concept here is the different adverse effects of erythromycin preparations. The estolate form is notorious for causing cholestatic hepatitis. The mechanism might involve the liver's metabolism, maybe affecting bile canaliculi.

Why is estolate the culprit? Well, estolate is a derivative that's more lipophilic, so it's more likely to accumulate in the liver. This can lead to damage in the bile ducts, causing cholestasis. The other forms, like ethylsuccinate or stearate, don't have this issue as much.

Looking at the wrong options: ethylsuccinate is used in children and is less likely to cause GI upset. Stearate is a topical form, so systemic effects are minimal. Lactobionate might be another form, but I'm not sure. Wait, lactobionate is a salt form, maybe used in solutions. But the main one causing cholestasis is estolate.

Clinical pearl: Remember that erythromycin estolate has a black box warning for cholestatic hepatitis. So in exams, when they mention cholestatic jaundice and erythromycin, estolate is the key.

Putting it all together: The correct answer is erythromycin estolate. The explanation should cover the mechanism, why other forms are safer, and the clinical importance.

**Core Concept**
The question tests knowledge of adverse effects of different erythromycin preparations. Erythromycin estolate is uniquely associated with cholestatic hepatitis due to its metabolic byproducts damaging bile canaliculi. This is a classic example of drug-induced liver injury.

**Why the Correct Answer is Right**
Erythromycin estolate undergoes hepatic metabolism to form a toxic ester metabolite, which accumulates in hepatocytes and disrupts bile flow, causing cholestasis. This leads to elevated conjugated bilirubin, alkaline phosphatase, and gamma-glutamyl transferase (GGT). The cholestatic pattern resolves after discontinuation but can progress to cirrhosis in severe cases.

**Why Each Wrong Option is Incorrect**
**Option A:** Erythromycin ethylsuccinate (oral) is less likely to cause cholestasis and is commonly used in pediatric populations.
**Option B:** Erythromycin stearate (topical) has minimal systemic absorption, avoiding hepatotoxicity.
**Option C:** Erythromycin lactobionate (IV) lacks the estolate ester group, reducing risk of cholestatic injury.

**Clinical Pearl / High-Yield Fact**
Erythromycin estolate has a black box warning for cholestatic hepatitis. Remember the mnemonic: "E for Estolate and Evil hepatitis." Always avoid estolate in patients

✓ Correct Answer: C. Erythromycin estolate